Lecanemab-irmb Approved for Alzheimer Disease
On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.
Vivjoa Approved for Recurrent Vulvovaginal Candidiasis
Oteseconazole is a treatment option for those living with a previously unmet medical need.
2 Commerce Drive Cranbury, NJ 08512